Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged Bayer, CDK2, CDK2 inhibitors, Cedilla, Cedilla Therapeutics, Cyclin Dependent Kinase 2, cyclin E, CyclinE1, CyclinE1/CDK2 complex inhibitors, Dominik Ruettinger, Exclusive license agreement, M.D., Neil Exter, oncogenic drivers, Ph.D., precision oncology
A new drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton. It has shown great promise in pre-clinical models and will be available to patients with certain leukaemias and non-Hodgkin … Read the full press release
Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged Amgen’s NEUPOGEN®, investigational biosimilar filgrastim, M.D., Mark McCamish, Ph.D., Sandoz
Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged David Meeker, Dr. Timothy Coetzee, Edward Fox, FDA, Genzyme, LemtradaTM (alemtuzumab), M.D., multiple sclerosis (MS), Ph.D., Sanofi
Annual General Meeting of Shareholders 2014 Mannheim, Germany, 21-5-2014 — /EuropaWire/ — The Annual General Meeting of Shareholders of SAP AG today approved all management proposals for the agenda items. With more than 99% of the votes, the shareholders approved the conversion … Read the full press release
Posted in Business, Financial, Germany, Management, Technology
Tagged and Prof. Dr.-Ing. Dr. Ing. E.h. Klaus Wucherer, Bernard Liautaud, Dr. Eberhard Schipporeit, Dr. h.c. Hartmut Mehdorn, European stock corporation, Jim Hagemann Snabe, Pekka Ala-Pietlä, Ph.D., Prof. Anja Feldmann, Prof. Dr. h.c. mult. Hasso Plattner, Prof. Dr. Wilhelm Haarmann, SAP, SAP shareholders, SE, Societas Europaea
Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global program underscores Sandoz’s leadership in biosimilars Holzkirchen, Germany, 1-7-2013 — /europawire.eu/ — Sandoz, the global … Read the full press release
25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged AstraZeneca, Cristina Rondinone, EEC, Inc., Jin-Long Chen, MedImmune, NGM, NGM Biopharmaceuticals, Ph.D.
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?